Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

a™ involves the remodeling of the actin cytoskeleton (F-actin) of endothelial cells (cells that line the inside of blood vessels, including the retinal blood vessels) so that the adhesion molecules between these cells are tightly bound to the peripheral actin (cortical) resulting in tighter junctions among these cells, hence preventing vascular leakage from the blood compartment into tissue. The basic mechanism of action of Optina™ is described in a recently published manuscript entitled: "Biphasic effect of danazol on human vascular endothelial cell permeability and f-actin cytoskeleton dynamics" in Biochemical Biophysical Research Communications (BBRC 21 April 2012 http://dx.doi.org/10.1016/j.bbrc.2012.04.066). This is the first in a series of publications describing the biphasic effect of danazol on vascular permeability which is beneficial in reducing permeability (nano molar concentrations) and increasing permeability at the higher concentrations used in other approved indications (micro molar).

Dr. Vaughan Clift, Ampio's Chief Regulatory Officer, noted, "A clinical study of Optina™ for DME conducted in a double masked, placebo controlled manner at Saint Michael Hospital in Toronto, Canada, confirmed the in vitro findings that the ultra-low dose of danazol is beneficial while the high dose is detrimental. Complete analysis of the Optina™ trial is underway by our CRO and results will be published in the proper venues following a pre-IND meeting with the FDA. Ampio is preparing for a pre-IND meeting with the FDA to discuss plans for a pivotal trial(s) in the US under the 505(b)2 registration."

About Diabetic Retinopathy, Diabetic Macular Edema and current treatments
Diabetic retinopathy is damage to the retina of the eyes caused by complications of diabetes mellitus and often resulting in loss of visual acuity and blindness.  Macular edema of th
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... WHIPPANY, N.J. , March 4, 2015 /PRNewswire/ ... and Drug Administration (FDA) has accepted the company,s ... recombinant Factor VIII compound.  Bayer is seeking FDA ... Kovaltry™, for the treatment of hemophilia A in ... committed to continually bringing new therapies to hemophilia ...
(Date:3/4/2015)... , March 4, 2015  Heska Corporation (Nasdaq: ... Invites You to Join Its Fourth Quarter and Year ... 5, 2015 @ 9:00 a.m. (MST) / 11:00 a.m. ... End 2014 Earnings Call link on the front page ... on to the web at the address above.  Alternatively, ...
(Date:3/4/2015)... 2015 Research and Markets ( ... "Negative Pressure Wound Therapy Market (Conventional and ... Size, Share, Growth, Trends and Forecast 2014 - ... The global negative pressure wound therapy ... geography. By product types the NPWT market is ...
Breaking Medicine Technology:FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3Webcast Alert: Heska Announces Fourth Quarter and Year End 2014 Earnings Conference Call Webcast 2Global Negative Pressure Wound Therapy (Conventional and Single Use NPWT Systems) Market Report 2014-2020 2
... , PLEASANTON, Calif. , Jan. ... world leader in device-based mechanical circulatory support (MCS) therapies to ... has acquired an innovative catheter pump technology that it plans ... cardiac axial flow pump that can be delivered percutaneously in ...
... , HOUSTON , Jan. 25 ... peacefully in his home on January 19th after ... Woodyard began his tenure at eCardio as Vice President, Business ... development initiatives. He was also responsible for identifying, negotiating and ...
Cached Medicine Technology:Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology 2Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology 3Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology 4Richard Woodyard, Vice President of Sales at eCardio, Loses Fight Against Cancer 2
(Date:3/4/2015)... March 04, 2015 FDA’s New Inspection ... **FDAnews Webinar**, March 24, 2015 — 1:30 p.m. – ... generally know within four hours of an inspection whether ... is on their “good” list, they’ll merely ask for ... manufacturer is on the “bad” list, the manufacturer must ...
(Date:3/4/2015)... Concord, NH (PRWEB) March 04, 2015 ... the natural frozen food category, will attend this year’s ... from its newest product line. With this new line, ... meals in the natural channel, continues its commitment to ... the fastest growing frozen brand in the natural channel, ...
(Date:3/4/2015)... 04, 2015 The print component of ... San Francisco Chronicle with a circulation of approximately 173,000 ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... Milorganite is composed of heat-dried microbes that have digested ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The New ... and lyrical music, will be performed by the award-winning ... Estates, CA, this March 6-22, 2015, on Fridays, Saturdays ... at Peninsula High School (27118 Silver Spur Road, ... hour before the program or may be purchased on-line ...
(Date:3/4/2015)... Columbus is no stranger to drug addiction. The ... addiction, and suffers from the potential threat of Kratom. In ... DEA revealed that Kratom is a “drug of concern.” Although ... introduced herb from Southeast Asia acts as a stimulant in ... kratom foments symptoms similar to heroin withdrawal, and includes tremors, ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 2Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 3Health News:The New Mel Brooks Musical Young Frankenstein Performance March 6-March 22, 2015, by the Award Winning Drama Department at Peninsula High School, Rolling Hills 2Health News:Columbus, OH Combats the Sale of Kratom as a Drug, Harbor Village Detox Stresses Caution 2
... , BATESVILLE, Ind., and ANDOVER, Mass., Sept. ... strategic partnership agreement to integrate the Radianse real-time location system ... this move, Hill-Rom intends to extend its leadership in health ... obstacles for health care customers as they consider high-precision, enterprise-wide ...
... ... Association (DIA) Study Endpoints Special Interest Area Community (SIAC) will host Measuring Study Endpoints ... Caregiver from October 26-27, 2009 in New Orleans, LA. , ... Horsham, PA (Vocus) September 2, 2009 ...
... Sept. 2 The following is an updated GlaxoSmithKline Consumer Healthcare statement ... orlistat: , , On August 24th the FDA ... serious adverse events. , , To view the Multimedia ... It,s important consumers know that alli is safe and effective ...
... , , , ... Sept. 2 /PRNewswire-FirstCall/ -- ... that is developing and marketing Levulan(R) Photodynamic Therapy (PDT) and other ... Doman, President and Chief Executive Officer, will present a corporate overview ...
... on their calls , TUESDAY, Sept. 1 (HealthDay ... research suggests they can appreciate music inspired by the ... similar to soothing monkey calls, the animals moved less ... distress calls, they became anxious. , This may not ...
... N.C., Sept. 2 Anpath Group, Inc. (OTC Bulletin Board: ANPG), ... joined the Board of Directors. , , Dr. ... care, specifically with HIV treatment and immunology. Currently he is ... Academy of HIV Medicine. In 2000, he founded his current ...
Cached Medicine News:Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 3Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 4Health News:Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 2Health News:Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 3Health News:Video: FDA States Consumers Should Continue to Use alli 2Health News:DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Health News:Scientists Make Sweet Monkey Music 2Health News:Dr. William J. Robbins Joins Anpath Group, Inc. Board of Directors 2Health News:Dr. William J. Robbins Joins Anpath Group, Inc. Board of Directors 3
... HeartMate II Left Ventricular Assist System (LVAS) ... shown to restore hemodynamic function and improve ... the rotary action of a single-moving part, ... full circulatory support by pumping blood from ...
... for movement is critical ... wheelchairs. Thats why this ... technology to do just ... state-of-the-art technology, these wheelchair ...
... standard to extra-wide wheelchairs (18" to 43") ... heavy-duty, anodized aluminum weighing platform is equipped ... easy access for large patients. Weight is ... readout. The 6772 has the unique features ...
When patients are less mobile our ProPlus™ Stand-On Scale with built-in wheels moves easily to them. Extremely durable and safe, the easy grip handrail and non-skid platform provide added suppo...
Medicine Products: